Vivos TherapeuticsVVOS
13F holders, Q1 2025 (March 31)21holders +1
6new positions
4sold out
$2.85avg. 13F price*
At the end of Q1 2025, 21 institutions reported holding Vivos Therapeutics Inc. (VVOS) in their 13F filings, up 1 from Q4 2024. 6 opened new positions and 4 sold out. The largest holders were B. Riley Wealth Advisors, Inc. ($198K), Geode Capital Management, LLC ($163K) and Cutter & CO Brokerage, Inc. ($140K).
- Company
- Vivos Therapeutics Inc.
- CUSIP
- 92859E207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $408K |
| Exits | 4 | $1.5M |
All 13F filers, Q4 2024 → Q1 2025: 227,519 shares bought and 343,149 shares sold, net −115,630 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 21 holders
| B. Riley Wealth Advisors, Inc. | 0.01% | New | 69,531 | $198K |
| Geode Capital Management, LLC | 0.00% | Add +27.9% | 57,349 | $163K |
| Cutter & CO Brokerage, Inc. | 0.03% | Add +28.9% | 49,100 | $140K |
| Vanguard Group Inc. | 0.00% | Add +303.0% | 42,634 | $122K |
| Envestnet Asset Management Inc. | 0.00% | New | 38,873 | $111K |
| Commonwealth Equity Services, LLC | 0.00% | Add +30.8% | 34,000 | $97K |
| Royal Bank of Canada | 0.00% | Add +450000.0% | 18,004 | $51K |
| Northern Trust Corp. | 0.00% | New | 12,511 | $36K |
| State Street Corp. | 0.00% | New | 11,822 | $34K |
| Ewa, LLC | 0.01% | New | 10,464 | $30K |
| Credit Agricole S A | 0.00% | No change | 2,365 | $7K |
| UBS Group AG | 0.00% | Add +383.0% | 1,879 | $5K |
| Morgan Stanley | 0.00% | Add +1675.7% | 1,314 | $4K |
| Signaturefd, LLC | 0.00% | No change | 547 | $2K |
| Group One Trading LLC | 0.00% | No change | 228 | $650 |
| Osaic Holdings, Inc. | 0.00% | Reduce -66.3% | 200 | $570 |
| Blue Trust, Inc. | 0.00% | No change | 160 | $456 |
| Bank of America Corp. | 0.00% | Add +8.3% | 130 | $370 |
| Kozak & Associates, Inc. | 0.00% | No change | 49 | $110 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 8 | $23 |
| Barclays PLC | 0.00% | New | 1 | $3 |
"% of holder's portfolio" is VVOS's weight in each manager's 13F, not the share of Vivos Therapeutics Inc. the manager owns.